Reports engineering of a thermosensitive lysostaphin–polypeptide fusion that forms a sustained-release depot and clears MRSA biofilm implant infections in animal models.
Key Takeaways
- Please note there may be errors present which affect the content, and all legal disclaimers apply
- We rationally engineered a chimeric Lst-ELP fusion protein that preserves potent lytic activity
- Thermosensitivity of Lst-ELP enables in situ formation of a sustained-release depot upon subcutaneous injection